VintaBio’s Post

Did you know that impurities are a major CMC challenge with current AAV manufacturing processes? I was thrilled to give a presentation at ESACT today about our new ELEVECTA technologies improving AAV quality and addressing the future challenges in the gene therapy space. We can have a chat around this at our booth #72 or contact me if you want to know more!

SURVEY: Making Decentralized Manufacturing a Reality Do you believe that decentralized manufacturing models are a realistic, commercially viable ambition? 👀 Let us know your thoughts on this and other critical questions that will help to build a roadmap to making decentralized manufacturing a reality for cell and gene therapy. If you have a few minutes, please share your perspective in this survey and we’ll send you a summary of the results! ➡️ https://hubs.ly/Q02d3mZV0 #Title21xGermfree #DecentralizedManufacturing #CellandGeneTherapy #PatientAccess #NearPatient #PointofCare

Consider this 𝗼𝗽𝗽𝗼𝗿𝘁𝘂𝗻𝗶𝘁𝘆 𝘁𝗼 𝗴𝗮𝗶𝗻 𝗶𝗻𝘀𝗶𝗴𝗵𝘁𝘀 𝗮𝗻𝗱 𝗰𝗼𝗻𝗻𝗲𝗰𝘁𝗶𝗼𝗻𝘀 that will drive the 𝘀𝘂𝗰𝗰𝗲𝘀𝘀𝗳𝘂𝗹 𝗹𝗮𝘂𝗻𝗰𝗵 𝗼𝗳 𝘁𝗵𝗲 𝗻𝗲𝘅𝘁 𝗴𝗲𝗻𝗲𝗿𝗮𝘁𝗶𝗼𝗻 𝗼𝗳 𝗰𝗲𝗹𝗹 𝗮𝗻𝗱 𝗴𝗲𝗻𝗲 𝘁𝗵𝗲𝗿𝗮𝗽𝘆 𝗽𝗿𝗼𝗱𝘂𝗰𝘁𝘀. My presentation will focus on setting apart your therapy for payers through science. My panel will discuss strategies for cross-functional collaboration. 𝗘𝘅𝗽𝗹𝗼𝗿𝗲 𝘁𝗵𝗲 𝗳𝘂𝗹𝗹 𝗮𝗴𝗲𝗻𝗱𝗮 𝗵𝗲𝗿𝗲 – https://ter.li/lhvjuu

Questions about applying #computervision in a commercial production setting?  Listen to Taylor Chartier’s presentation the morning of March 6th at #IFPAC to hear about common use cases and compliance to improve cell and gene therapy quality control. Link shared below in comments.  See you in the audience or afterwards at our booth! #genetherapy #ai #qualitycontrol #gxp

Calling all employee benefit leaders and consultants, the Integrated Benefits Institute (IBI) would like to understand your perspectives on cell and gene therapies and information interests related to clinical innovation and costs. Your feedback is critical and the survey will take less than five minutes! https://lnkd.in/e4fS3eP7 The survey is for all individuals no matter their depth of cell and gene therapy knowledge or experience. Aggregate study findings will be shared broadly and help inform the development of future materials. #humanresources #employeewellbeing #celltherapy #genetherapy

Drew Wilkins To my network of benefits professionals -- especially organization benefits managers, directors, VPs of TR, and CHROs! Cell and Gene Therapies are the next big issue to tackle. Please take this quick survey to let us know your thoughts and perspectives. https://lnkd.in/e4fS3eP7

Watch now: https://lnkd.in/gT3Wfkb2 Boost your gene therapy development with a quick quality control step! Watch our Image Lab video tutorial to learn how to assess AAV capsid protein ratios efficiently. Set parameters, estimate protein size, and let Image Lab Software do the rest. Check it out now! #GeneTherapy #AAVResearch #QualityControl

One week to go until the experts in market access, regulatory affairs, and non-clinical strategy at the Cell and Gene Therapy Catapult will be delivering a webinar on 'Developing a robust target product profile (TPP) for successful therapy adoption'. If you are looking to improve your understanding of the characteristics of a TPP, attending this webinar is essential to learn how to create your own robust #TPP and increase the likelihood of successful adoption of your #AdvancedTherapy. Learn more: https://buff.ly/3RqT2nC ##TPP #CGTDeveloper #CellTherapies #GeneTherapies

Attn: Benefits folks! The number of FDA approved cell & gene therapies is expected to more than quadruple by 2032 (85 new gene therapies across more than 12 therapeutic areas). What info do you need to best inform your future benefit decisions? Share your perspectives in Integrated Benefits Institute's 5-minute study below 👇